FDA’s January 2026 Digital Health Guidance Updates

Expanded Opportunities for Wellness and Clinical Decision Support Software

In January 2026, the U.S. Food and Drug Administration (FDA) released updated guidance documents for General Wellness: Policy for Low Risk Devices and Clinical Decision Support (CDS) Software, providing greater clarity on when certain digital health products fall outside the scope of FDA medical device regulation. These updates are part of the agency’s broader effort to encourage innovation in digital health technologies while maintaining appropriate safeguards for patient safety.

For developers of software-driven health tools, wearables, and artificial intelligence–enabled platforms, the updated guidance may open new pathways to market without the need for prior FDA marketing authorization. However, these policies do not represent deregulation in the traditional sense. Rather, they reinforce a risk-based regulatory approach, emphasizing that manufacturers must carefully evaluate a product’s intended use, functionality, and risk profile against the criteria described in the guidance documents.

Understanding these nuances is essential for determining whether a product qualifies for enforcement discretion or exemption from device regulation.

Expanded Scope of the General Wellness Policy

The FDA’s General Wellness guidance describes a category of low-risk products that promote healthy lifestyles or general wellness but do not make claims related to diagnosing, treating, or preventing specific diseases. Products that fall within this category are typically not subject to FDA oversight as medical devices.

The 2026 update provides additional clarity on the types of technologies that may qualify as general wellness products, particularly in the rapidly evolving wearable and digital health ecosystem. The agency continues to emphasize two primary criteria:

1. The product must be intended only for general wellness use, such as promoting healthy habits or improving overall well-being.

2. The product must present low risk to users, meaning that the technologies used to achieve their intended use would be unlikely to cause harm.
   

Examples of technologies that may fall under the general wellness policy include:

• Wearable fitness trackers that monitor daily activity levels and encourage users to increase step counts.

• Sleep tracking applications that provide insights on sleep patterns and offer suggestions for improving sleep hygiene.

• Stress management apps that guide breathing exercises or meditation based on heart rate variability trends.

• Recovery and training optimization wearables that display physiological trends (such as resting heart rate or recovery scores) to help users adjust workouts.

• Nutrition or hydration reminder apps that encourage healthier lifestyle habits.
  

In the updated framework, some wearable features that track physiological metrics may still fall within the general wellness category as long as they are presented in a lifestyle context rather than as medical measurements. For example:

• A wearable displaying blood pressure trends to guide workout recovery could potentially fall under general wellness if it is not marketed as a diagnostic blood pressure monitor.

• A smartwatch providing oxygen saturation trends to help users understand recovery during exercise may also qualify if it avoids medical claims.
  

However, the regulatory status can change quickly if the intended use crosses into disease-related territory. A device that claims to detect or treat specific disease conditions such as hypertension, sleep apnea, or manage diabetes would still be regulated as a medical device that requires marketing authorization (e.g., 510(k) or De Novo).

Clarifications in the Clinical Decision Support Software Guidance

The updated Clinical Decision Support guidance focuses on software that assists healthcare professionals in making clinical decisions. Under the 21st Century Cures Act, certain CDS software functions are excluded from the statutory definition of a medical device if they meet specific criteria. (U.S. Food and Drug Administration)

To qualify for this exclusion, the software must meet four key conditions:

1. It must not analyze medical images, signals, or data from diagnostic devices.

    

2. It must display or analyze medical information such as clinical guidelines or patient data.

    

3. It must provide recommendations to support clinical decision-making, rather than independently making decisions.

4. It must allow healthcare professionals to independently review the basis of the recommendations.

One notable clarification in the 2026 guidance is that the FDA may exercise enforcement discretion for certain CDS tools that present a single recommended option, provided the clinician can still understand and evaluate the underlying rationale.

Examples of software functions that may now fall outside FDA regulation include:

• Medication dosing support tools that calculate recommended dosages using established clinical guidelines.

• Drug–drug interaction alert systems embedded in electronic health records.

• Guideline-based treatment recommendation engines that suggest therapies based on patient characteristics and published clinical evidence.

• Risk stratification calculators that estimate cardiovascular risk using validated scoring systems.

• Clinical workflow tools that recommend appropriate diagnostic tests based on documented symptoms and guideline logic.

However, CDS software that performs advanced analysis of medical images, physiologic signals, or other complex diagnostic data generally remains within FDA’s regulatory scope. For example:

• AI software interpreting radiology images to detect cancer

• Algorithms analyzing ECG signals to diagnose arrhythmias

• Software predicting disease based on raw physiologic sensor data

These types of functions typically require regulatory oversight because clinicians may not be able to independently review the algorithm’s reasoning.

Why Intended Use and Risk Assessment Matter

While the updated guidance expands the range of technologies that may qualify for reduced regulatory oversight, developers should not interpret these policies as a blanket exemption for digital health tools.

In practice, the distinction between a regulated medical device and a non-device function often hinges on small but critical differences in intended use statements, claims, and system design.

For example:

These distinctions illustrate why manufacturers must conduct a thorough regulatory assessment early in product development. 

Practical Considerations for Developers

Companies developing digital health technologies should carefully evaluate several factors before determining whether their product falls within these guidance policies:

• Intended use statements and marketing claims

• Target user population (consumer vs. healthcare professional)

• Type of data analyzed (general wellness metrics vs. medical signals)

• Transparency and explainability of algorithms

• Potential patient safety risks if the output is incorrect
  

In many cases, subtle design decisions—such as whether clinicians can independently review the reasoning behind a recommendation—may determine whether a product is regulated as a medical device.

Conclusion

The FDA’s January 2026 updates to the General Wellness and Clinical Decision Support guidance documents reflect the agency’s continued effort to foster innovation in digital health technologies. By clarifying which products fall outside medical device regulation, the guidance provides greater flexibility for developers of wellness tools and decision-support software.

However, the expanded scope of these policies also increases the importance of careful regulatory evaluation. A product that appears to qualify for the general wellness or non-device CDS categories may still be regulated if its intended use, claims, or technical functionality introduces medical risk.

For companies developing digital health technologies, the key takeaway is clear: regulatory strategy must begin with a rigorous assessment of intended use and risk. While the 2026 guidance may open new opportunities to bring innovative products to market more quickly, ensuring alignment with FDA expectations remains critical to long-term success.